Healthcare / BiotechnologyTaipei Exchange
$28.80
+0.20 (+0.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $27.1M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$738M
P/E
17.5x
↓EV/EBITDA
11.9x
↓ROE
9.3%
↑Gross Margin
39.9%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.6%
FCF CAGR
-12.5%
FCF margin
10.3%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $262.7M · net income $42.4M · FCF $27.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $262.7M | $262.7M | $292.5M | $264.7M | $235.9M |
| Net Income | $42.4M | $42.4M | $44.0M | $49.7M | $42.3M |
| EBITDA | $63.1M | $63.1M | $67.6M | $73.9M | $64.2M |
| EPS | — | — | 1.72 | 1.94 | 1.65 |
| Gross Margin | 39.9% | 39.9% | 39.2% | 39.4% | 44.3% |
| Operating Margin | 18.3% | 18.3% | 19.0% | 19.2% | 20.9% |
| Net Margin | 16.2% | 16.2% | 15.1% | 18.8% | 17.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.24 | 0.13 | 0.15 |
| Current Ratio | 3.93 | 3.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $27.1M | $27.1M | $931000.00 | $27.8M | $40.4M |
| Returns | |||||
| ROE | 9.3% | 9.3% | 9.8% | 10.8% | 9.3% |
| Valuation | |||||
| P/E | 17.45 | 17.45 | 19.36 | 17.37 | 18.12 |
| EV/EBITDA | 11.89 | 11.89 | 12.63 | 10.56 | 10.33 |
| P/B | 1.61 | 1.61 | 1.90 | 1.87 | 1.68 |
| Growth & Yield | |||||
| Revenue Growth | -10.2% | -10.2% | 10.5% | 12.2% | — |
| EPS Growth | — | — | -11.3% | 17.6% | — |
| Dividend Yield | 5.1% | 5.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.0%
Start / end P/E
n/dx → n/dx
EPS bridge
1.72 → n/d
Residual
-15.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.